

## COMIRNATY CLINICAL TRIAL

July 27, 2020 - October 29, 2020

	Comirnaty	Placebo	Absolute/Relative Effectiveness
Group size	22,030	22,030	
Severe Adverse Events	264 1.20%	154 0.70%	-71% -0.50%
Cases (with prior infection)	2 0.01%	7 0.03%	71% 0.02%
Severe Cases	1 0.00%	30 0.14%	97% 0.13%
Deaths	15 0.07%	14 0.06%	-7% 0.00%
Severe Adverse Events / Severe Cases	14x		
Severe Adverse Events / Cases (with prior infection)	47x		

<https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1.full-text>

<https://www.nejm.org/doi/full/10.1056/nejmoa2034577>

### Delta-variant SARS-CoV2 breakthrough infections following vaccination BNY162b2

“infectiousness protection starts diminishing for patients two months post vaccination and ultimately vanishes for patients 6 months or longer post vaccination.”

<https://www.medrxiv.org/content/10.1101/2021.08.29.21262798v1>

### Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel

“Conclusions These results indicate a strong effect of waning immunity in all age groups after six months.”

<https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1>

### Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger...

“Collectively, these findings suggest that the established two-dose vaccination regimen elicits less durable immune responses in the elderly compared to young adults.”

<https://www.medrxiv.org/content/10.1101/2021.08.26.21262468v1>

### Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

<https://pubmed.ncbi.nlm.nih.gov/16115318/>

### Emerging Evidence Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

“Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance.”

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/>